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ABSTRACT: Metabolomics is a rapidly evolving analytical approach in
life and health sciences. The structural elucidation of the metabolites of
interest remains a major analytical challenge in the metabolomics
workflow. Here, we investigate the use of ion mobility as a tool to aid
metabolite identification. Ion mobility allows for the measurement of the
rotationally averaged collision cross-section (CCS), which gives
information about the ionic shape of a molecule in the gas phase. We
measured the CCSs of 125 common metabolites using traveling-wave ion
mobility-mass spectrometry (TW-IM-MS). CCS measurements were
highly reproducible on instruments located in three independent
laboratories (RSD < 5% for 99%). We also determined the reproducibility
of CCS measurements in various biological matrixes including urine,
plasma, platelets, and red blood cells using ultra performance liquid
chromatography (UPLC) coupled with TW-IM-MS. The mean RSD was < 2% for 97% of the CCS values, compared to 80% of
retention times. Finally, as proof of concept, we used UPLC−TW-IM-MS to compare the cellular metabolome of epithelial and
mesenchymal cells, an in vitro model used to study cancer development. Experimentally determined and computationally derived
CCS values were used as orthogonal analytical parameters in combination with retention time and accurate mass information to
confirm the identity of key metabolites potentially involved in cancer. Thus, our results indicate that adding CCS data to
searchable databases and to routine metabolomics workflows will increase the identification confidence compared to traditional
analytical approaches.
Metabolomics, a powerful analytical strategy in transla-tional medicine and biomarker discovery, relies on
advanced technology to profile metabolites in cells, tissues, and
biofluids.1−3 The confident identification of these metabolites
on a high-throughput scale, however, remains a major analytical
challenge because of their chemical and structural diversity.
Thus, implementing workflows that involve orthogonal
analytical tools might facilitate metabolite identification.4
Mass spectrometry (MS) is a widely used technique for
analyzing small molecules.5 Because of the complexity of the
metabolome, MS-based metabolomics analyses are usually
performed in conjunction with liquid chromatography (LC).5
Analyzing hydrophilic compounds by means of traditional
reversed-phase LC−MS is not ideal as these metabolites are
poorly retained and usually elute in the void volume.6,7 On the
other hand, it has been demonstrated that hydrophilic
interaction liquid chromatography−MS (HILIC−MS) im-
proves resolution, identification, and quantification for these
types of compounds.7−10 Intersample variability caused by
using different matrixes and sample loading, however, can lead
to shifts in retention times, which complicates the use of
retention time for identification purposes.
The coupling of UPLC with ion mobility MS (UPLC−IM-
MS) is a promising analytical technique within the field of
metabolomics.11−16 Ion mobility spectrometry is a gas-phase
electrophoretic technique that separates ions according to their
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charge, shape, and size. Ion separation occurs in the millisecond
time frame, making it compatible with time-of-flight mass
spectrometry. The CCS17 for a given ion can be derived by
measuring the time required for an ion to traverse a chamber
filled with an inert gas. The CCS value is a unique
physicochemical property of a molecule. Using CCS as an
orthogonal molecular descriptor in addition to retention time
and mass-to-charge ratio (m/z) offers the opportunity to
further improve the identification process, making it more
robust and reproducible across multiple samples and time-
frames.13−16,18−23 Such an approach remains largely unexplored
in metabolomics applications.
During this study, we incorporated ion mobility into the
UPLC−MS, metabolomics workflow. We generated a CCS
database of common cellular metabolites, validated across
multiple laboratories, which was ultimately used to confidently
identify the metabolic alterations related to the epithelial−
mesenchymal transition process. Our study highlights the
benefit of using ion mobility in metabolomics
■ EXPERIMENTAL SECTION
Chemicals. All materials were obtained from Sigma-Aldrich
(Germany) unless stated otherwise. Acetonitrile (ACN) was
purchased from Merck KGaA, (Darmstadt, Germany). Water
was obtained using an 18 Ω m Milli-Q (EMD Millipore
Corporation, Billerica, MA). All chemicals and solvents were of
analytical grade or higher purity. Poly-DL-alanine (product
number P9003) was purchased from Sigma-Aldrich (U.K.).
Platelets (PLT), red blood cells (RBC), and plasma were
obtained from the Blood Bank, Landspitali-University Hospital,
Reykjavik, Iceland). Urine was obtained from a male volunteer.
This study was approved by the National Bioethics Committee
of Iceland and the Icelandic Data Protection Authority.
Sample Preparation. Standard Mixtures. Mixtures
containing between 10 and 15 standard metabolites (each
with a different molecular weight) were prepared in H2O/ACN
(50:50, v:v), at a concentration of 10 mg/L.
Biological Samples. A volume of 0.5 mL of PLT and RBC
concentrates were used to extract intracellular metabolites using
methanol (MeOH)/H2O (7:3, v:v), as previously described.
7
The supernatant was dried and reconstituted in 0.3 mL of
H2O/ACN (50:50, v:v). Plasma samples (0.3 mL) were
processed by adding 0.9 mL of MeOH. After centrifugation
(10 min, 4 °C, 10 000g), the supernatant was dried and
reconstituted in 0.15 mL of H2O/ACN (50:50, v:v). Urine
samples (0.2 mL) were processed adding 0.6 mL of MeOH.
After centrifugation (10 min, 4 °C, 10 000g), the supernatant
was dried and reconstituted in 0.5 mL of H2O/ACN (50:50,
v:v).
Cell Culture. D492 breast epithelial cells and D492M,
epithelially derived mesenchymal cells were cultured as
previously described.24 Briefly, cells were cultured to confluency
in H14 medium at 37 °C and 5% CO2. After 3 days in culture,
the cells were trypsinized, collected by centrifugation, counted,
and washed three times with PBS. Intracellular metabolites
were extracted using MeOH/H2O (7:3 v:v) as previously
described.7
MS Analysis. Three traveling-wave ion mobility mass
spectrometers (TW-IM-MS)25 (Synapt G2 HDMS, Waters
Corporation, Manchester, U.K.) located in independent
laboratories were used to derive CCS information for a variety
of small low molecular weight, polar metabolites (Table S1 in
the Supporting Information).
The first Synapt HDMS system was located in Durham, NC.
In positive electrospray mode, the capillary and cone voltage
were 2.6 kV and 35 V, respectively. The source and desolvation
temperatures were 100 and 150 °C, respectively, and the
desolvation gas flow was 600 L/h. Nitrogen, the IMS gas,
flowed at a rate of 90 mL/min (3.2 mbar), with a wave velocity
of 600 m/s and wave height of 40 V. In negative electrospray
mode, the capillary and cone voltage were 2.3 kV and 25 V,
respectively. The source and desolvation temperature were 100
and 150 °C, respectively, and the desolvation gas flow was 600
L/h. Nitrogen, the IMS gas, flowed at a rate of 90 mL/min (3.2
mbar), with a wave velocity of 650 m/s and wave height of 40
V. The EDC delay coefficient was specified as 1.36 V in positive
mode and as 1.41 in negative mode. In both positive and
negative mode, direct injection at a flow rate of 0.75 μL/min
was used.
The second Synapt HDMS system was located in Man-
chester, U.K. In positive electrospray mode, the capillary and
cone voltage were 2.5 kV and 30 V, respectively. The source
and desolvation temperature were 100 and 250 °C, respectively,
and the desolvation gas flow was 600 L/h. Nitrogen, the IMS
gas, flowed at a rate of 90 mL/min (3.2 mbar), with a wave
velocity of 750 m/s and wave height of 40 V. In negative
electrospray mode, the capillary and cone voltage were 2 kV
and 40 V, respectively. The source and desolvation temperature
were 100 and 250 °C, respectively, and the desolvation gas flow
was 600 L/h. Nitrogen, the IMS gas, flowed at a rate of 90 mL/
min (3.2 mbar), with a wave velocity of 800 m/s and wave
height of 40 V. The EDC delay coefficient was specified as 1.58
V. Direct injection at a flow rate of 5 μL/min was used in both
positive and negative mode.
The third Synapt HDMS system was located in Reykjavik,
Iceland. In positive electrospray mode, the capillary and cone
voltage were 1.5 kV and 30 V, respectively. The source and
desolvation temperature were 120 and 500 °C, respectively, and
the desolvation gas flow was 800 L/h. Nitrogen, the IMS gas,
flowed at a rate of 90 mL/min (3.2 mbar), with a wave velocity
of 600 m/s and wave height of 32 V. In negative electrospray
mode, the capillary and cone voltage were 1.5 kV and 30 V,
respectively. The source and desolvation temperature were 120
and 500 °C, respectively, and the desolvation gas flow was 800
L/h. Nitrogen, the IMS gas, flowed at a rate of 90 mL/min (3.2
mbar), with a wave velocity of 600 m/s and wave height of 32
V. The EDC delay coefficient was specified as 1.58 V. Argon
served as collision gas in both positive and negative mode.
During HDMSE experiments, the collision energy in the trap
cell was 4 eV (Function 1), and in the transfer cell, it ranged
from 20 to 30 eV (Function 2). In both positive and negative
mode, direct injection, at a flow rate of 0.75 μL/min, or UPLC
was used.
Liquid Chromatographic Analysis. Chromatographic
separation was achieved using an ACQUITY UPLC system
(UPLC ACQUITY, Waters Corporation, Milford, MA) and
hydrophilic-interaction liquid chromatography (HILIC) using a
1.7-μm (2.1 mm × 150 mm) ACQUITY amide column
(Waters Corporation). Samples and standard mixtures were
analyzed three times in UPLC−HILIC-HDMSE, once in
positive ionization mode and twice in negative ionization
mode using acidic and basic chromatographic conditions,
respectively. In positive mode and in negative acidic conditions
alike, mobile phase A was 100% ACN and mobile phase B was
100% H2O, with both containing 0.1% formic acid. The
following elution gradient was used: 0 min, 99% A; 6 min, 40%
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A; 8 min, 99% A; 10 min, 99% A. In negative-mode basic
conditions, mobile phase A contained ACN/sodium bicar-
bonate, 10 mM (95:5) and mobile phase B contained ACN/
sodium bicarbonate, 10 mM (5:95). The following elution
gradient was used: 0 min, 99% A; 5 min, 42% A; 6 min, 70% A;
7 min, 99%; 10 min, 99% A. In all conditions, the flow rate was
0.4 mL/min, the column temperature 45 °C, and the injection
volume 3.5 μL.
CCS Measurements for Metabolites. CCS values
obtained in nitrogen were experimentally determined using
previously published CCS values for singly charged polyalanine
oligomers as the TW mobility calibrant26,27 (Table S2,
Supporting Information). Experimental procedures for measur-
ing CCS are outlined in Figure S1 (see the Supporting
Information for more details). Poly-DL-alanine was used as the
calibrant species in both electrospray positive (ES+) and ES−
and was prepared in H2O/ACN (50:50, v:v) at a concentration
of 10 mg/L. Calibration was performed using oligomers from n
= 3 to n = 11, covering a mass range from 231 to 799 Da and a
CCS range from 151 Å2 to 306 Å2 in ES+ and from 150 Å2 to
308 Å2 in ES− (Table S2, Supporting Information).26 CCSs
were derived using a procedure previously reported.26 The ion
mobility resolution was ∼40 (fwhm). The ion mobility peak or
arrival time distribution (ATD) may represent a combination of
structurally similar isomers that remain unresolved. The CCS
values reported were determined at the apex of the ion mobility
peak or ATD. The use of different ionization sources (causing
different interferences that are not resolved) and/or different
mobility calibrants could lead to slight variations in the
reported CCS.28
Prediction of CCS via Computational Methods.
Theoretical collisional cross sections were calculated as follows.
First, two- dimensional (2D) structures for the compounds
were downloaded from NCBI’s PubChem database29 in SD file
format. Following this, ChemAxon’s (ChemAxon, 5.4.1.1.) pKa
module was used to calculate the most acidic or most basic
atom in each 2D structure. Protonated and sodiated forms were
generated by connecting a hydrogen or a sodium atom to the
most basic atom in the 2D structure. The formal charge of the
most basic atom was then set to +1. Similarly, a hydrogen
attached to the most acidic atom was disconnected to generate
deprotonated structures. Then, ChemAxon’s conformer plugin
was used to generate molecular mechanics (using MMFF94
force field) based lowest energy conformers. Each molecular
mechanics based minimum energy conformer was reoptimized
with the density functional theory B3LYP/6-31g*. Density
functional calculations were done with Gaussian09.30 All
structure manipulations (generation of ionized forms and
molecular mechanics based conformers) and input file
preparations (for Gaussian09 and Mobcal) were done using
MolFind’s tools panel.31 Finally, a modified version of
Mobcal32−34 optimized according to the room temperature
N2-based trajectory method (TM) was used for calculating
average collision cross-sectional areas.
Data Processing and Analysis. Progenesis QI v1.0
(Nonlinear Dynamics, Newcastle, U.K.) was used for visual-
Figure 1. CCS measurements for 125 common metabolites: (a) visual representation of the metabolites analyzed in this study (red dots) according
to their metabolic position in a KEGG metabolic map. (b) Classes of cellular metabolites included in this study. (c) Correlation between CCS and
mass values. Both CCS value in negative and positive modes were used, and sodium adducts were excluded except for sugars: amino acids and
derivatives (n = 55, R = 0.91); carboxylic acids (n = 9, R = 0.90); nucleobases (n = 16, R = 0.88); phosphorylated compounds (n = 15, R = 0.84);
sugar (n = 13, R = 0.99); sugar sodium adducts (n = 12, R = 0.99); nucleosides (n = 19, R = 0.94); nucleotides (n = 23, R = 0.81). (d) Correlation
between experimentally derived and computationally predicted CCS values.
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ization, processing, and interpretation of multidimensional IM-
MS data. Each UPLC−IM-MS run was imported as an ion
intensity map, including m/z and retention time. These ion
maps were then aligned in the retention time direction. From
the aligned runs, Progenesis QI produces an aggregate run that
was representative of the compounds in all samples and used
this aggregate run for peak picking. The peak picking from this
aggregate was then propagated to all runs, so that the same ions
are detected in every run. Isotope and adduct deconvolution
was applied to reduce the number of features detected. Data
were normalized using total ion intensity. The software was
coded to directly convert drift time data into CCS values using
the polyalanine calibration curve. Statistically significant
alterations were identified using multivariate statistics, including
principal components analysis (PCA) and orthogonal partial
least square-discriminant analysis (OPLS-DA) and further
confirmed using analysis of variance (ANOVA). Metabolites
were identified by searching in the Human Metabolome
Database (HMDB),35 METLIN,36,37 and in-house databases
with Δppm < 10, retention time range < 0.3 s, and ΔCCS < 5
Å2 as tolerance parameters. Fragment ion mass spectra were
analyzed in both MSE and HDMSE mode.
■ RESULTS AND DISCUSSION
Investigating the use of ion mobility to support metabolomic
applications, we conducted a multilaboratory study to obtain
the CCS values of 125 standard metabolites, using both
experimentally derived and computationally calculated ap-
proaches. This data was used to create a unique database,
which contained not only retention time and m/z information,
but also CCS values for each structure. In order to validate the
database and its unique capabilities, we conducted metab-
olomics analyses of biological samples using the additional CCS
information to aid in the identification of metabolites.
Experimentally- and Computationally Derived CCSs
of Common Metabolites. Experimental procedures for
measuring CCSs are based on calibration with compounds
having known CCS values as reported in the Experimental
Section (Figure S1, Supporting Information). In order to
represent the chemical complexity of the cellular metabolome,
we selected as unknowns 125 metabolites representing key
metabolic pathways. These metabolites included sugars,
phosphorylated compounds, purines and pyrimidines, nucleo-
tides, nucleosides, acylcarnitines, carboxylic acids, hydrophilic
vitamins and amino acids (Figure 1 and Table S3 in the
Supporting Information). We measured drift times in nitrogen
for these metabolites using TW-IM-MS instruments located in
three independent laboratories (Table S4, Supporting In-
formation). We then derived CCS values using polyalanine
oligomers as mobility calibrants in both positive and negative
ES mode of operation. The polyalanine standards allowed us to
correct for variation in drift times between instruments located
in different laboratories and having different ion mobility
Figure 2. Reproducibility of CCS measurements across different instruments: (a) different drift time values for reduced glutathione were obtained
using different TW-IM parameter settings. The use of polyalanine as calibrators corrected the final CCSs measurements. (b) Relative standard
deviation (RSD%) for CCS measurements across three independent laboratories.
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parameter settings (Figure 2a). We derived 209 CCS values (96
in positive and 113 in negative ion mode) with an
interlaboratory RSD% lower than 5% for 99% of the
measurements (Figure 2b). These results support the
proposition that a CCS value derived from calibration is an
absolute measurement, representing a physicochemical prop-
erty that is consistent across a range of experimental and
instrumental conditions. Experimentally derived CCS values
highlighted trend lines related to different chemical classes
(Figure 1c). Furthermore, experimentally derived CCS values
correlated closely with theoretical CCS calculated using Mobcal
(Figure 1d and Table S4, Supporting Information).
Generation of a Database Containing Retention Time,
CCS, and m/z Values. To allow a more comprehensive LC
separation of the different classes of compounds used in this
study, we coupled UPLC with TW-IM-MS. Notably, the
analysis of polar metabolites using traditional reversed-phase
LC−MS presents some challenges because they are poorly
retained and usually eluted in the void volume.6−10 Two
different HILIC methods (i.e., acidic and basic) were used (for
details see the Experimental Section). Basic conditions were
chosen to separate phosphorylated compounds, such as
nucleotides and sugar phosphates, which under acidic
conditions were strongly retained, resulting in poor chromato-
graphic peak shape.7,8 Using HILIC conditions, our set of polar
metabolites eluted in order of increasing polarity (Table S3,
Supporting Information). For each of the 125 compounds
included in this study, we annotated values for accurate mass,
CCS, and retention time, creating a database that was then used
to analyze biological samples.
Application of Ion Mobility-Derived Information to
the Analysis of Biological Samples. To evaluate the
applicability of this approach to metabolomic applications, we
analyzed plasma, urine, red blood cells (RBCs), and platelets
(PLTs) using UPLC−TW-IM-MS. In these experiments, we
calculated the ΔCCS (the difference between the database CCS
and the experimental CCS) and used this as a contribution to
the identification score in addition to retention time and
accurate mass. This enabled us to search for metabolites whose
identifications have a CCS error less than a given threshold.
Thus, we were able to filter and score identifications when
querying our database with CCS information. Using CCS,
retention time, and accurate mass as orthogonal coordinates, a
total of 94 different metabolites were confirmed to be present
in the various biological matrixes (48 in plasma, 46 in urine, 74
in RBCs, and 71 in PLTs).
The retention time of a given metabolite can change from
one run to the next due to experimental drift (e.g., room/
column temperature and degradation of the column). More-
over, different sample matrixes can influence the reproducibility
of retention times, largely due to different salt and lipid
contents. Figure 3a shows the extracted-ion chromatogram of
arginine in different matrixes, highlighting the effect of the
matrix on retention time. In Figure 3b, we present the
extracted-ion chromatogram resulting from the ion mobility
separation showing the absence of the matrix effect on drift
Figure 3. Matrix effect on retention times compared to CCSs: (a) extracted-ion chromatograms and (b) extracted-ion mobility chromatograms of
arginine analyzed in four different biological matrixes (plasma, red blood cells, platelets, and urine). (c) Retention times reproducibility and (d)
CCSs reproducibility in the various biological matrixes.
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time. Our results showed a RSD% <2 for 97% of the CCS
measurements, compared with 80% for the retention time
values, suggesting that CCS measurements are more stable and
reliable than retention time and thus may add more confidence
in the identification process during metabolomics experiments
(Figure 3c,d).
To confirm the identity of the metabolites, we performed the
analysis using data-independent or UPLC−“MSE” mode of
acquisition, which alternates between a low and elevated
collision energy regime. At low collision energy, the exact mass
measurements of unfragmented precursor ions are obtained,
whereas at the elevated collision energy, the product ions for all
precursors are obtained.38,39 In biological samples, however,
multiple analytes often have indistinguishable retention times.
Consequently, applying elevated collision energy in MSE mode
might lead to the generation of product ions derived from
multiple precursor ions at a given retention time, complicating
the identification process (Figure S2, Supporting Information).
To overcome this problem, we used a combination of MSE and
ion mobility, HDMSE, which allows the drift time separation of
coeluting precursor metabolites before the fragmentation
process takes place. Precursor ions and fragment ions were
ion mobility-aligned to filter out fragments that do not match
the precursor’s drift time. Precursor separation was important
for obtaining a cleaner collision-induced dissociation spectrum
that is not contaminated from a mixture of coeluting
compounds. The use of ion mobility thus provided a simplified
and cleaned product ion spectrum that facilitated the
identification process (Figure S2, Supporting Information).
HDMSE ultimately resulted in a better performance in terms of
converting feature detected in metabolites identified, increasing
the ratio feature/metabolites compared to a typical LC−MS.40
Such results are in agreement with previous studies showing
that HDMSE provides better clarity and depth of coverage for
the analysis of complex samples compared to regular MS
approaches.41−43 In an in depth analysis of the precision and
accuracy of HDMSE, it has been shown that with ion mobility
activated, the number of ion detections and accurate-mass
retention-time pairs increased at an average rate of 24.4 and
26.6%, respectively, while at the same time, the average number
of ion interference events dropped from 20.2 to 5.4%.41−43
Application of Ion Mobility-Derived Information to
Metabolomics. We applied the approach described above to
investigate the metabolic alterations occurring during the
epithelial−mesenchymal transition process. Such a process
occurs during embryonic development whereby epithelial cells
acquire mesenchymal, fibroblast-like properties and display
reduced intracellular adhesion and increased motility. It is also
Figure 4. Experimentally determined CCS information in support of metabolite identification. Retention times, m/z, CCS, isotopic pattern, and
fragmentation information were used to identify metabolites that had a statistically significant alteration during the epithelial−mesenchymal
transition process: (a) overlaid, extracted-ion chromatograms of inosine and guanosine in epithelial and mesenchymal cells. (b) Low- and high-
energy spectra for inosine in HDMSE mode. (c) Low- and high-energy spectra for guanosine in HDMSE mode. Data processing and analysis
performed using Progenesis QI v1.0.
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the means by which malignant epithelial tumors metasta-
size.24,44,45 This tightly regulated process is associated with a
number of cellular and molecular events, many of which are not
yet characterized.
In order to shed light on the metabolic events leading to the
differentiation of epithelial and mesenchymal cells, we
compared the metabolome of D492 breast epithelial cells (n
= 4) with that of D492 M epithelially derived mesenchymal
cells (n = 4) using HILIC UPLC−TW-IM-MS. Data processing
and analysis highlighted three molecular features as major
contributors to the variance between epithelial and mesen-
chymal cells (Figure 4 and Figure S3, Supporting Information).
The accurate-mass measurements of these discriminating
features were searched against HMDB and METLIN and
resulted in a list of potential identifications based on accurate-
mass error (<5 ppm). Review of such a list was supported by
the use of HDMSE fragmentation spectra, retention time, and
isotopic pattern deviation (Figure 4). Drift time data of
unknown species were directly converted to CCS values by
calibrating with polyalanine ions of known CCS, providing an
additional coordinate for metabolite characterization (Figure 4
and Figure S3, Supporting Information). Comparing the
experimental CCS values with those reported in our database,
we were able to confirm the identity of inosine and guanosine
as two of the features of interest (ΔCCS = 0.1% Å2 for inosine
and ΔCCS = 0.4% Å2 for guanosine) (Figure 4). The third
molecular feature at m/z 135.0309 was identified as a
hypoxanthine-like fragment derived from in-source breakdown
of inosine (Figure 4). These results indicate that CCS can be
used as an orthogonal analytical parameter alongside the
traditional molecular identifiers of precursor accurate mass,
fragment ion accurate mass, isotope pattern, and chromato-
graphic retention time as a confirmation of metabolite identity
to increase the confidence of identification.46
An obvious limitation of this approach is that it is impractical
to prepare a completely comprehensive database containing
experimental CCS’s for all compounds present across
metabolomes. An alternative strategy that would potentially
alleviate this problem is the use of computationally predicted
CCSs.31 In cases where mass measurements and Δppm are not
able to differentiate between potential candidate metabolites
obtained from a database search, a comparison between the
experimental and theoretical CCS values can support the
identification process. As an example, the accurate m/z at
267.0728 for inosine was searched against the HMDB and
METLIN database leading to four potential candidates, with
Δppm < 5 ppm (Table 1). Three out of the four matches had
identical Δppm values but different CCS values. In such a case,
ΔtCCS (the difference between the theoretical CCS and the
experimental CCS) was used to filter the potential candidates,
increasing the confidence of identification for inosine (the
compound with the lowest ΔtCCS, Table 1). These results
indicate that computationally predicted CCS might be used as
an indicator of compound structure to aid metabolite
identification during searches in large metabolite database,
potentially reducing the number of false positive and false
negative identifications.
■ CONCLUSIONS
In this study, we integrated ion mobility into a typical LC−MS-
based workflow for routine metabolomics applications. The use
of ion mobility in combination with UPLC−MS and UPLC−
MS/MS increased the system peak capacity and specificity for
metabolite identification. Ion mobility was used to measure
CCS values for 125 metabolites across three independent
laboratories, demonstrating high intra- and interlaboratory
reproducibility. The creation of a searchable database for
metabolites that includes CCS as an orthogonal analytical
measurement, in addition to retention time and m/z, increased
the confidence of metabolite identification compared to
traditional LC−MS approaches. Metabolomics applications
using direct infusion or desorption ionization sources in
combination with TW-IM-MS could particularly benefit from
the use of CCS-containing databases to support metabolite
identification.20,47−49 We encourage further studies to extend
and populate existing metabolite databases with CCS values for
metabolomics and other small molecules applications.
Table 1. List of Potential Metabolite Candidates for m/z 267.0728 after a Search in the HMDB Database with a Cutoff of 5
ppma
aTheoretical CCS values were compared with the experimental CCS value for inosine to generate ΔtCCS in support of mass measurement to aid
metabolite identification. Three-dimensional structures of energy-minimized metabolites showing the different conformations after molecular
modeling.
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